Cargando…

Successful Treatment of Chronic Eosinophilic Pneumonia with Anti-IgE Therapy

Anti-IgE therapy, using recombinant humanized anti-IgE antibodies, is clinically effective in patients with eosinophil-related disorders such as allergic asthma, allergic rhinitis, and chronic urticaria. Chronic eosinophilic pneumonia tends to respond promptly to systemic corticosteroid therapy, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Yoo Seob, Jin, Hyun Jung, Yoo, Hye-Soo, Hwang, Eui-kyung, Nam, Young Hee, Ye, Young-Min, Park, Hae-Sim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468766/
https://www.ncbi.nlm.nih.gov/pubmed/23091327
http://dx.doi.org/10.3346/jkms.2012.27.10.1261
Descripción
Sumario:Anti-IgE therapy, using recombinant humanized anti-IgE antibodies, is clinically effective in patients with eosinophil-related disorders such as allergic asthma, allergic rhinitis, and chronic urticaria. Chronic eosinophilic pneumonia tends to respond promptly to systemic corticosteroid therapy, however; relapses are common following corticosteroid tapering. We treated two patients (17- and 19-yr-old males) of chronic eosinophilic pneumonia whose symptoms were cough and dyspnea on exertion. The symptoms were recurrent while tapering off corticosteroid. They were treated with anti-IgE antibody without recurrence for 2 yr and 15 months. Here, we first describe clinical experience of the 2 cases of chronic eosinophilic pneumonia.